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ABSTRACT 
 
Myocardial infarction results in tissue necrosis, leading to cell loss and 
ultimately to cardiac failure.  Implantation of immature progenitor cells into the 
scar area may compensate for the cell loss and provides a new therapeutic 
avenue for infarct treatment.  Premature myoblasts derived from skeletal 
muscle are one of the best candidates for this therapeutic purpose, because 
biopsies used for autologous cell therapy can be accessed easily, the isolated 
myoblasts can proliferate well in vitro, and the skeletal and cardiac muscles 
are structurally and functionally similar.  
 
In this study we investigated the survival and differentiation of the 
implanted skeletal myoblasts in the non-cryoinjured myocardium and the 
myocardial scar, using a syngeneic Lewis rat model.  A therapeutic dose of 
4x106 skeletal myoblasts/animal was implanted into the non-cryoinjured and 
scar tissue, and the fate of the implant was monitored at 12, 28 and 56 days 
after implantation by immunohistochemistry.  We detected fast myosin heavy 
chain (fMHC) expression at each time point but significantly fewer positive 
cells in the scar than in the non-injured tissue.  This was consistent with the 
staining patterns of slow myosin heavy chain (sMHC) and myogenin that 
overlapped with fMHC positive areas.  Although the implanted myoblasts 
differentiated into skeletal muscle cells, they did not transdifferentiate into 
 iii
cardiac muscle, demonstrated by the absence of cardiac troponin I 
expression.   
 During this analysis we developed a model, which could be useful to 
test new strategies for myoblast implantation (dosage, genetic modification, 
new injection technique etc.) designed to promote better engraftment of 
cultured myoblasts in the myocardial scar.   
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BACKGROUND 
 
The heart is a unique organ with a very high metabolic rate and 
oxygen consumption.  It has its own vessel system to supply the myocardium 
with nutrients and oxygen, thereby maintaining its functional and structural 
integrity.  The heart receives blood directly from the aorta through two main 
coronaries: the left and the right.  The left coronary artery and its descending 
arteries are particularly important, because these vessels supply the bigger 
part of the left ventricle.  The left anterior descending (LAD) artery is one of 
the main branches of the left coronary artery, supplying blood to the anterior 
wall of the left ventricle.   
 
Myocardial infarction (MI) occurs when the heart muscle experiences a 
sudden substantial blood supply interruption.  This results in necrotic death of 
cardiomyocytes which are very sensitive to oxygen deprivation.  The 
myocardial necrosis is followed by an inflammatory process, and then 
neutrophils and macrophages infiltrate the dead tissue.  During the healing 
process, capillaries and fibroblasts populate the damaged myocardium and 
form the granulation tissue.  As the fibroblasts excrete increasing amounts of 
collagen and the vessels resorb, the infarct becomes remodeled and several 
weeks later the myocardium is replaced with low cellularity fibrotic tissue.  
This remodeling has an effect on the surviving myocytes, because they take 
over the function of the lost tissue by hypertrophy (Olivetti et al., 1991).  
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These structural changes lead to functional alterations such as increased left 
ventricle end-diastolic volume and decreased ejection fraction (Nahrendorf et 
al., 2001; Nilsson et al., 2002).  Overall, the structural and functional 
alterations can ultimately result in cardiac failure and death.   
 
Traditional treatments with beta-blockers and vaso-dilators can slow 
down the progression of cardiac dysfunction, but cannot restore the heart’s 
performance.  Replacement of the scar tissue by cells that have the same or 
similar properties as the cardiomyocytes is a novel approach for MI treatment.  
These cells can derive from embryonic tissue such as immature totipotent 
cells or from adult bone marrow such as multipotent cells, or from other 
tissues.  Such cell implantation into the damaged myocardium has been 
shown to improve the overall heart function in several animal models 
(Soonpaa et al., 1994; Taylor et al., 1998; Scorsin et al., 2000; Etzion et al., 
2001).  Fetal cardiomyocyte implantation into the myocardial scar was shown 
to increase the left ventricle ejection fraction (Scorsin et al., 2000) and may 
limit the scar expansion (Li et al., 2001).  Additionally, the implanted cells may 
potentially integrate into the host myocardium.  Bone marrow derived cells 
that can be autologous, were also shown to survive in the scar, reduce left 
ventricle remodeling and improve overall cardiac function (Wang et al., 2000; 
Kocher et al., 2001; Orlic et al., 2001).   
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Skeletal myoblasts are another attractive cell type for infarction-related 
cell therapy.  They can be used as an autologous transplant and therefore 
there is no need for immunosuppression.  In addition, skeletal myoblasts 
have been widely explored and shown to functionally contribute to the heart, 
most often in rat or rabbit animal models (Taylor et al., 1998; Li et al., 2001).  
Skeletal myoblasts were shown to differentiate in the heart and express 
skeletal muscle specific markers such as myogenin (Atkins et al., 1999; 
Atkins et al., 1999) and fast skeletal myosin heavy chain (fMHC) (Scorsin et 
al., 2000; Reinecke et al., 2002).  Furthermore, the implanted cells appear to 
decrease scar stiffness and increase diastolic properties in several MI animal 
models (Rando et al., 1994; Taylor et al., 1998; Atkins et al., 1999; Atkins et 
al., 1999; Atkins et al., 1999; Scorsin et al., 2000).   
 
Histologically and functionally striated muscle can be divided into two 
distinct groups: cardiac muscle and skeletal muscle.  Cardiac muscle is 
comprised of cardiomyocytes, which may be multinucleated as a result of 
incomplete cell division.  In contrast, skeletal muscle cell consists of 
multinucleated myofibers formed by myoblast fusion.  Both types of striated 
muscle can generate high power output and both contain sarcomeres of thick 
and thin myofilaments.  Although there are structural similarities between the 
cardiac and skeletal muscles, they have significant differences in their 
electrochemical activation which evokes a mechanical response in muscle.  
Cardiac myocytes, unlike skeletal muscle cells, are connected to each other 
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by low resistance intercellular gap junctions and have the ability to spread the 
electric activity from cardiomyocyte to cardiomyocyte.  Contraction of cardiac 
muscle is spontaneous and involuntary, and maintained paced by electrical 
impulses of the sinoatrial node.  In contrast, the skeletal muscle is voluntary 
and controlled by the peripheral portion of the central nervous system.  A 
muscle fiber is connected to a motor nerve at the neuromuscular junction.  
The innervation is responsible not only for the muscle movements, but also 
for proper muscle formation and maturation.  Moreover, upon denervation the 
skeletal muscle atrophies and degenerates.  The skeletal muscle also has a 
noteworthy potential to regenerate after an injury with the help of reserve 
mesenchyme cells called satellite cells (Jones, 1979; Allbrook, 1981).  
Cardiac muscle, in its turn, has very little, if any, regenerative capability (Nag 
et al., 1983).   
 
Satellite cells were discovered in the 1960’s using electron microscopy 
(Mauro, 1961).  During muscle growth or injury, a new population of 
myoblasts is generated from satellite cells by division.  The differentiating 
myoblasts fuse into already existing myofibers resulting in muscle growth and 
tissue repair.  The development of myoblasts is associated with expression of 
several stage-specific muscle markers.  Early-on, proliferating skeletal 
myoblasts express an ~50kD muscle specific intermediate filament protein 
called desmin (Lazarides et al., 1976; Hubbard et al., 1979).  Since desmin is 
continuously expressed in both immature and differentiated muscle cells, it is 
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a useful myogenic lineage marker both in vivo and in vitro.  A set of myogenic 
regulatory factors (MRFs) including MyoD, myogenin, Myf5 and MRF4 is 
important in myogenic development.  Importantly, expression of these 
proteins can convert non-myogenic cells into myoblasts in vitro (Davis et al., 
1987).  In activated satellite cells, Myf5 and MyoD are expressed in early 
development, while myogenin and MRF4 appear only when the cells undergo 
differentiation (Hinterberger et al., 1991; Koishi et al., 1995; Lindon et al., 
1998).  During in vitro differentiation, the myoblasts fuse to form 
multinucleated myotubes and express several other muscle specific proteins.  
Myosin heavy chain (MHC) is one of the earliest proteins expressed in the 
differentiating muscle cell.  MHC is a part of the thick filament and its eight 
different isoforms have been identified in differentiated muscles.  Myosin is 
the main component of the sarcomere and represents about 20% of the total 
muscle protein mass (Nadal-Ginard, 1978).  It is an ATP-binding protein and 
consumes ATP during contraction.  Isoforms can be classified based on 
different ATPase activities (Staron et al., 1986; Rivero et al., 1999; Karasinski 
et al., 2001).  The expression of the isoforms is development- and tissue-type 
specific (Reiser et al., 1988; Hughes et al., 1993; Russell et al., 1993).  The 
adult myocardium abundantly expresses slow MHC (sMHC or beta-MHC) as 
well as some cardiac MHC (alpha-MHC).  In contrast, the adult skeletal 
muscle expresses both the slow and fast isoforms of MHC (Perrie et al., 
1986).  The innervation plays an important role in expression of myosin 
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isoforms, since regenerating muscle fibers cannot express slow MHC without 
motor innervation (Yoshimura et al., 1998).   
 
To investigate myocardial events and potential treatment options, 
several different animal infarct models have been developed.  These models 
induce tissue necrosis in two ways.  One is the occlusion model in which the 
coronary artery descendants are ligated (Selye, 1960; Eaton et al., 1981; Yue 
et al., 1998; Scorsin et al., 2000; Nahrendorf et al., 2001).  There are two 
types of ligation: permanent ligation of the LAD or temporary ligation called 
ischemia- reperfusion.  The ligation model is similar to naturally occuring of 
MI.  However, the collateral system of the LAD differs greatly among species 
and individual animals, and therefore the infarction size created by LAD 
ligation results in highly individual variations (Johns, 1954).  The other MI 
generation technique is called cryothermia.  This kind of injury to the 
myocardium by local hypothermia is induced with a cold probe (-160°C), and 
generates a controlled lesion of a predictable size (Hass, 1948).  In addition, 
the scar generated in such a way is homogenous and well defined.  Though 
this is not a physiological MI model, its cellular healing pattern is similar to 
that of the myocardial infarction (Jensen et al., 1987).   
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PROJECT PURPOSE 
 
 The goal of this project therefore was to compare the survival and 
differentiation of skeletal myoblasts in the non-cryoinjured myocardium and 
the myocardial scar. 
 
 Skeletal myoblast implantation into the myocardium is a potential 
therapy for mitigating pathological remodeling after myocardial infarction.  
The myocardium itself however is not a natural setting for skeletal muscle to 
reside, because it has no somatic innervation.  Furthermore, skeletal 
myoblasts are implanted into the myocardial scar, which is a hostile 
environment lacking blood supply, nutrients and oxygen.  This might lead to 
decreased survival of the implanted cells.  
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MATERIALS AND METHODS 
 
Animals 
Male inbred Lewis rats (224–245 g) were obtained from Charles River 
Laboratories, Inc., Quebec, Canada.  
 
Cell isolation and cultivation 
Myoblasts were isolated from tibialis anterior (TA) muscles in the lower 
hind limb area of male Lewis rats due to the easy access and identification of 
this muscle during pretreatment and tissue harvest.  Satellite cell proliferation 
was stimulated by inducing tissue damage of the TA muscles with bupivicaine 
hydrochloride, 0.5%, (Marcaine, Astra) injection three days before harvest 
under anesthesia.  Aseptically removed muscles were placed into storage 
medium (1 µg/ml amphotericin B, 10 µg/ml gentamicin, Ham’s F-12 nutrient 
mixture) and stored at 4°C for 2-4 days prior to isolation because the 
myoblast yield is higher from stored tissue as compared with the freshly 
processed one (unpublished observation).  Then the muscles were trimmed 
of tendon and fat, weighed and finely minced to <2 mm pieces.  Then the 
tissue was enzymatically dissociated in collagenase type II solution 
(Worthington) at a concentration of 8300 U/g tissue at 37°C for a total of 1 h 
with vigorous shaking every 20 min.  Then the remaining tissue pieces were 
further digested in 0.25% Trypsin-EDTA (17 ml/g tissue) for 20 min at 37°C.  
The released cells were separated from tissue debris by being passed 
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through a 10 µm vacuum sieve and preplated onto polystyrene surface for 2 h 
at 45 mg (predigestion tissue weight) per cm2 density to reduce the fibroblast 
number.  Non-adherent cells were then replated onto collagen type I coated 
culture vessels (BD Biosciences) at a density of 15 mg tissue/cm2. We used 
collagen type I coated surface to promote the attachment and prevent 
differentiation of myoblasts.  The cells were cultured in 1 µg/ml 
amphotericin B and 10 µg/ml gentamicin containing 20% FBS/ Ham’s F-12 
medium that was supplemented with 5 ng/ml of bFGF and other growth 
factors, as indicated in the RESULTS section.  Cells were collected from 
culture vessels with 0.5% Trypsin-EDTA at low confluence (~60-80%) and 
passaged or cryopreserved in freezing medium (10% DMSO, 40% Ham’s F-
12 and 50% FBS) and stored in liquid nitrogen for later use.   
In differentiation experiments cells were cultured in 2% FBS/F-12 
medium with no additional growth factors for variable amount of time (2-7 
days).  
 
Cell count and viability 
At the end of each passage the total cell number was determined by 
cell counting in a hemocytometer.  The proliferation rate was calculated by 
using the following equation: ln(N/ N0-2)/ t, where N is final cell density, N0 is 
starting cell density, and t is culturing time (days). 
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Cell viability was determined by Trypan blue exclusion by mixing equal 
volumes of cell suspension and 0.4% Trypan Blue stain (Gibco BRL) and 
incubating for 5 min at RT.  Unstained (viable) and stained (dead) cells were 
counted separately.  Cell viability was expressed as a percentage of the total 
cell number. 
 
Cell fixation 
Representative aliquots of harvested cells (2x106) were fixed with 4% 
paraformaldehyde/ phosphate buffered saline (PFA/PBS) solution (EMS, 
USA) for 20 min at RT.  Then the samples were washed and stored in PBS at 
4°C and processed later.   
Cells grown on culture slides were fixed in situ as described above.   
 
FACS analysis 
Immunostaining for FACS analysis was performed in saponin 
permeabilization buffer (0.1% Saponin and 10% FBS in PBS) on PFA fixed 
cells.  First, cells were incubated with the selected diluted primary antibody 
(monoclonal mouse anti-human desmin or monoclonal mouse anti-rat 
myogenin) at RT for 30 min.  Then after a wash in PBS the cells were 
incubated with FITC-conjugated anti-mouse secondary antibody at 4°C for 30 
min in the dark.  At the end of the incubation the cells were washed with PBS 
and stored at 4°C before being analyzed by FACS.  Flow cytometry 
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measurements were performed using FACStar Plus (Becton Dickinson) and 
the data were analyzed with Cell Quest software.   
 
Myocardial infarction 
Cryoinjury was performed on anesthetized animals.  The thorax was 
opened and the heart was exposed.  The 1 cm2 oval cryoprobe filled with 
liquid nitrogen was placed onto the lower mid-third of LV in two series.  The 
first series consisted of 5 15-second freezing intervals, each several seconds 
apart, and the second 12-15 60-second intervals.  Then the muscle layer and 
the skin were closed with sutures and the animals were placed under heating 
lamps until they recovered from anesthesia and were intensively observed for 
4 h.  After the surgery each animal received antibiotics (benzathine penicillin 
G and procaine penicillin G, 200,000 U/kg body weight) and pain medication 
(buprenorphine, 0.01-0.05 mg/kg body weight). 
 
Cell preparation for implantation 
Shortly before transplantation, cryopreserved cells for two animals (a 
cryoinjured and a non-cryoinjured) were thawed and pooled in the first wash 
solution (20% FBS/Iscove’s modified Dubelcco’s medium (IMDM)) at a 
density of 0.2x106 cells/ml.  Then they were washed twice in injection solution 
(0.5% culture grade BSA/IMDM) at a density of 0.8x106 cells/ml.  The cells 
were collected from suspension by centrifugation at 1700 rpm (450xg) for 
7 min.  At the final washing step a small aliquot of cells was taken for cell 
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counting and viability test, and the rest of the cell suspension was divided into 
two equal portions for injection.  The cells were then collected into pellets, 
resuspended in 50 µl of injection solution and stored on ice for injection up to 
3 hours later.  
 
Cell implantation 
Three weeks after cryoinjury the animals were anesthetized again and 
prepared for cell implantation.  The chest cavity was opened close to the first 
incision and the cryoinjured area was identified by white coloration of the scar 
tissue  (Figure 1).  Cells were injected with an insulin syringe into a single 
location in the middle of the scar.  In the non-cryoinjured animals, cells were 
injected into the lower third of the left ventricle, equivalent area to the infarct 
zone.  After closing the thorax the animals recovered under heating lamps 
and received the same post-operative care and medication as at the time of 
cryoinjury.   
 
Figure 1.  Cryoinjured heart exposed 
for cell injection.  Pale area on the 
heart surface (shown by arrow) denotes 
the scar tissue.   
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All surgical procedures (cryoinjury and cell implantation) were 
performed by the same surgeon in order to minimize individual variations.   
 
Heart harvest 
At different post-implantation time points (12, 28 and 56 days) animals 
were deeply anesthetized.  The chest cavity was then opened and the heart 
was exposed.  The heart was stopped in diastole with 30 mM KCl solution 
injected it into one of the vena cava.  Then heart was removed from the chest 
cavity and further perfused with the same KCl solution at 4° C.  This perfusion 
removed the blood from the tissue, helping to achieve better histological 
quality of the histological sections.  Additionally, animals were heparinized 
prior to organ harvest, which inhibited blood clotting and enabled better tissue 
cleanup.  After perfusion, a latex balloon was inserted into the left ventricle 
and brought up to the pressure of 10 mm Hg to prevent the collapse of the 
chambers and obtain better histological review of the sections.  Finally the 
heart was perfused with 4% PFA and further fixed by immersing into the 
same fixative for 48-72 hours at RT.   
 
Heart sectioning 
The heart trimmed of the atria was further sectioned into three equal 
portions.  Tissue was processed, paraffin embedded and miscrodissected by 
Histo Techniques Inc.  The detailed histological sectioning is described in the 
RESULTS section.   
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Immunohistochemistry 
Immunostainings were performed on cultured cells and tissue sections.   
Immunocytochemistry was performed on cells grown on culture slides 
and fixed in situ with 4% PFA.  Then cells were permeabilized with 0.5% 
TritonX/PBS at 4°C for 5 min before the endogenous peroxidase activity was 
quenched with 0.3% H2O2/70% methanol at RT for 30 min.  Then the slides 
were rinsed and soaked in distilled water.  The immunostaining was 
performed according to the instruction manual of the Elite ABC  
immunostaining kit (Vector Laboratories).  All incubations listed below were 
executed at RT.  The primary and secondary antibodies were diluted in 
blocking buffer (5% normal horse serum/ Cadenza buffer (Shandon-
Immunon)).  Briefly, the slides were incubated in blocking buffer for 30 min, 
then with the diluted primary antibody for further 30 min.  After several 
washes the slides were incubated with secondary, biotinylated antibodies for 
an additional 30 min, and then again for 30 min with the Avidin Biotin 
Complex (ABC) reagent.  The color reaction was developed with DAB 
Chromogen solution (Shandon-Immunon).  The color reagent was diluted as 
specified in the kit protocol and incubated with the specimens for 2-10 min.  
Color development was controlled by microscopic viewing of the positive 
control and the reaction was stopped by diluting the DAB substrate with 
water.  The slides then were counterstained with hematoxylin and 
coverslipped for viewing and storage.  Table 1 summarizes all the primary 
antibodies used in this study. 
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Antigen Antibody Dilutions Application 
1:50 FACS samples Desmin 
 
Monoclonal mouse anti-
human desmin (DAKO) 1:200 Cultured cells (in situ 
staining) 
1:50 FACS samples Myogenin 
 
Monoclonal mouse anti-rat 
myogenin (DAKO) 1:200 Tissue sections,  
Fast Myosin 
Heavy Chain 
Monoclonal mouse anti-rabbit 
fast skeletal myosin (Sigma) 
1:3000 Cultured cells (in situ 
staining) 
Slow Myosin 
Heavy Chain 
Monoclonal mouse anti-
human slow muscle myosin 
(Chemicon International Inc.) 
1:200 Tissue sections 
Cardiac 
Troponin I 
Monoclonal mouse anti-
human cardiac troponin I 
(Spectral) 
1:200 Tissue sections 
 
 
 
Immunohistochemistry of tissue sections was similar to the procedure 
described above, although the slides were first deparaffinized and rehydrated 
by being dipped sequentially in the following solvents: first, 100% xylene for 6 
min, then 100% ethanol for 4 min, followed by 95% ethanol for 2 min, 70 % 
ethanol for 2 min and finally distilled water for at least 2 min.  Then the slides 
were incubated in 0.1% SDS solution at 90-95°C for 40 min for antigen 
unmasking.  This procedure was followed by a distilled water wash step and 
the further procedures as described in Immunocytochemistry section.  Again, 
immunostaining was carried out using the Elite ABC antibody staining kit 
(Vector Laboratories).   
Table 1.  Primary antibodies used in the study. 
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Image analysis 
Sections were scanned with a Polaroid Sprintscan device using the 
Pkware Sprintscan software (resolution 2700 DPI, 100% scaling).  Image 
brightness was adjusted using Microsoft Photo Editor.  The area of interest 
was cropped out with Adobe Photoshop for image analysis using 
MetaMorph 5.0r software.  The color threshold for fMHC staining was 
determined for several sections and kept constant during the evaluation.  
However, due to some small variations between the samples, it was finely 
tuned for the individual samples.  Moreover, this adjustment was carefully 
performed without over- or under-detecting the positively stained areas.  The 
staining abundance was expressed in pixels by MetaMorph 5.0r.  The total 
tissue area and infarct areas were similarly measured by the same program. 
 
Statistical analysis 
Raw data was compared using ANOVA software.  It was transformed 
by taking the square roots before performing the paired t-test.  
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RESULTS 
 
Generation of myoblast banks 
 
Isolation of skeletal myoblasts 
Two strains of cultured rat skeletal myoblasts (R021102 and 
R121100AT) were isolated during this study as described in MATERIALS 
AND METHODS section.  The isolation conditions are summarized in Table 
3A and their cultivation is described in Preparation of cell banks section. 
 
Characterization of cultured myoblasts by growth and light microscopic 
morphology 
The freshly isolated cells did not divide for 2-3 days, leading to slower 
proliferation of passage 1 cells, than later passage cells.  Most of the cells in 
this early passage showed characteristic spindle-shape morphology (Figure 
2a) and often colony formation.  However, in older cultures the cells stretched 
out and a spontaneous cell fusion into myotube occurred, indicating myoblast 
differentiation (Figure 2b).  The multinucleated myotubes lose their ability to 
proliferate and they are more vulnerable to physical insults occurring during 
culture passages and cell implantation.  Therefore, cells were routinely 
passaged at low confluence (~70%), when they had not yet differentiated.  
Additionally, our early experimental goal was to establish culture conditions 
that promote proliferation, but prevent differentiation of myoblasts.  
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Modulation of proliferation and myoblast content by growth factors  
Application of the basic growth medium (5 ng/ml bFGF, 20% FBS), 
which was used in the laboratory for cultivation of primary muscle cells, 
resulted in significant variations in myoblast content.  Therefore, additional 
growth factors were tested, to potentially increase the myoblast number, 
either by increasing proliferation or by preventing differentiation.  bFGF has 
been reported to promote myoblast proliferation in different species (Doumit 
et al., 1993; Maley et al., 1995), whereas TGF-beta is known as an inhibitor of 
muscle differentiation (Maley et al., 1995; Bouche et al., 2000; Liu et al., 
2001).  Dexamethasone has been tested less intensively, but in skeletal 
myoblast cultures both the proliferation promoting and the differentiation 
inhibiting effects were observed (Guerriero et al.,1978; Guerriero et al., 1980; 
Gossett et al., 1988; Whitson et al., 1989).  Therefore, we added TGF-beta 
and/or dexamethasone to the basal culture medium.  To compare their 
a b
Figure 2 Morphology of cultured rat skeletal myoblasts (light microscopy 
20x magnification). Figure (a): early culture of passage 1 cells in 20% FBS /F-12 with 5 ng/ml 
bFGF; (b) differentiated cells after 2 days in reduced serum (2%) medium.  
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effects, second passage of R021102 cells were equally plated and 
simultaneously cultured in different growth media as listed below: 
a) 5 ng/ml bFGF, 20% FBS/F-12 
b) 5 ng/ml bFGF and 1 ng/ml TGF, 20% FBS/F-12  
c) 5 ng/ml bFGF and 10-6 M dexamethasone, 20% FBS/F-12  
d) 5 ng/ml bFGF, 1 ng/ml TGF-beta and 10-6 M dexamethasone, 
20% FBS/F-12 
The exponentially growing cultures were harvested 3 days after plating.  
The proliferation rate and myoblast content were determined as described in 
the next sections.   
 
Growth effect 
 We determined the rate of cell proliferation in different growth 
conditions by cell count.  The cell yield was normalized to the culture surface 
(Table 2).  The basic condition, 5 ng/ml bFGF in 20% FBS/F-12 produced 
2.65x104 cell/cm2 harvest density.  In contrast, when dexamethasone was 
present in the culture medium, the cell yield increased to 7.88x104 cell/cm2 
(Table 2).  TGF-beta had a reverse effect on proliferation and the cell yield 
decreased to 1.59x104 cell/cm2.  This growth suppressive effect of TGF-beta 
was still detectable in the presence of dexamethasone (5.92x104 cell/cm2).   
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Condition TGF-beta 
1ng/ml 
Dexamethasone 
10-6M 
Yield, 
x104 
cells/cm2 
Growth rate 
(doublings/day) 
Desmin 
positive 
population, %
a - - 2.60 0.72 23 
b + - 1.59 0.48 29 
c - + 7.88 1.25 50 
d + + 5.92 1.11 49 
 
 
Effect on myoblast content 
Desmin content  
 To determine the myoblast content in the cultures, we performed flow 
cytometry on desmin stained cells.  The intermediate filament protein desmin 
is a myogenic lineage marker, and it is expressed in proliferating muscle cells 
that are committed to muscle development.  To monitor the effect of different 
growth factors on the myoblast pool, at the end of the culture period aliquots 
of the samples were processed for flow cytometric analysis.   
A typical FACS profile of desmin-stained cultured muscle cells consists 
of two, well-separated peaks, corresponding to desmin positive and negative 
cells (Figure 3).  A non-relevant antibody as negative control was included in 
all stainings to determine the fluorescent signal threshold in the assay (not 
Table 2.  Effects of growth factors on proliferation of cultured rat skeletal myoblasts (n=1). 
All culture conditions (a-d) contained 5 ng/ml of bFGF in 20%FBS/F-12 and individual cultures 
also were supplemented with 1 ng/ml TGF-beta (b), 10-6M dexamethasone (c) and both 1 ng/ml 
TGF-beta and 10-6M dexamethasone (d). Cell yield, growth rate, and desmin content were 
determined for each condition.   
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shown).  Changes in the histogram profile under different growth conditions 
are shown in Figure 3.  The % desmin positive cells in cultures is also 
summarized in Table 2.  Both dexamethasone (Figure 3c) and TGF-beta 
(Figure 3b) increased the desmin pool in comparison with the basic 
conditions (Figure 3a).  However, the dexamethasone effect was more 
pronounced (50%) and doubled the desmin content of the population.  
Moreover, simultaneous application of TGF-beta and dexamethasone did not 
further increase the desmin content (Figure 4d) when compared to the only 
dexamethasone treatment (Figure 3c, 49% vs. 50%).  These results were 
reproducible (data not shown). 
 The distribution of desmin content was similar in differentiating 
and proliferating cultures, (Figure 3 aa-dd) (also see In vitro differentiation 
section).  However, it was reduced in each differentiated culture when 
compared to its proliferating counterpart.  The highest desmin containing 
differentiating culture was that, grown in the presence of dexamethasone 
(31%, Figure 3cc). TGF-beta moderately increased the desmin content of the 
differentiating cultures (17% Figure 3bb) when compared to the basic 
condition (9%, Figure 3aa). 
The reduced desmin content of the differentiating as opposed to the 
proliferating cultures may be related to the shorter life time of differentiated 
cells or the possible inability of these multinucleated myotubes to pass 
through the flow cytometer.   
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Figure 3. Effects of growth factors on desmin population of R021102 cells by FACS 
analysis (n=1).  R021102 cells were cultured in media with different growth factors for 3 
days (a-d).  All media contained 20% FBS/Ham’s F-12 and 5 ng/ml bFGF and (a) no 
additional growth factors, (b) 1 ng/ml TGF-beta; (c) 10-6 M dexamethasone; (d) 1 ng/ml TGF-
beta and 10-6 M dexamethasone.  Simultaneous proliferating cultures (aa-dd, grown with the 
same growth factors as cultures a-d), were also induced to differentiate in reduced serum 
(2%) medium without any growth factors, for 3 days.  The x-axis represents fluorescence 
intensity and y-axis designates cell number.  Desmin content (percentage of positive cells) in 
cultures is indicated in an insert in each histogram.  The M1 line marks the desmin positive 
peak in each population.  The position of the negative peak was determined by staining with 
irrelevant primary antibody (not shown). 
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Myogenin content 
 To obtain further evidence that the cultures had a myogenic potential, 
we also investigated the expression of myogenin, another muscle specific 
marker, with FACS analysis.  Myogenin staining did not result in easily 
detectable positive and negative peaks in growing cultures (Figure 4).  The 
poor separation may be related to the weak signal due to the fact that 
myogenin is expressed only in the nucleus, and fluorescence emitted by  the 
nuclei gets lost in the background of autofluorescence of negative cells.  
Since only a small fraction of myoblasts in proliferating cultures contain 
myogenin, and due to its transient expression during the differentiation, the 
myogenin staining has some limitations.   
In differentiating cultures the histogram profile did not significantly 
change.  Although the myogenin FACS always indicated a smaller myogenic 
pool (Figure 4 aa-dd) in the same culture than the desmin FACS, the 
myogenin content showed the same apparent distribution under the 
investigated culture conditions as desmin.  The highest myogenin positive 
pool was observed in the culture that was grown in the presence of 
dexamethasone before differentiation (Figure 4 cc).  TGF-beta also appeared 
to increase the proportion of myogenic cells when compared to the basic 
condition (10% in Figure 4 bb vs. 6% in Figure 4 aa).  
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Figure 4.  Effects of growth factors on myogenin population of R021102 cells by FACS 
analysis (n=1).  R021102 cells were cultured in media with different growth factors for 3 days 
as described in Figure 3.  We were not able to obtain data from (b) culture due to a small cell 
number in the sample.  Myogenin content (percentage of positive cells) in cultures is indicated 
in an insert in each histogram. The M1 line marks the desmin positive peak in each population. 
The position of the negative peak was determined by staining with irrelevant primary antibody 
(not shown). 
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In vitro differentiation 
To analyze the ability of cultured myoblasts to differentiate an in vitro 
assay was performed.  First, the differentiated cells were harvested and their 
desmin and myogenin content was determined by flow cytometry as 
discussed in Desmin content and Myogenin content sections.  In this assay 
all the four culture conditions (see section Modulation of proliferation and 
myoblast content by growth factors, conditions a-d) were tested.  Growth of 
these cultures was first facilitated by a variety of growth factors, and then 
differentiation was induced by 2% FBS/F-12 containing medium for 3 days 
before harvest. 
 The second test was performed only with selected cultures and 
the morphological changes associated with differentiation were examined.  
Previous assays demonstrated the growth promoting effect of 
dexamethasone.  In this test the differentiation ability of the dexamethasone-
induced large desmin positive population was investigated.  For this purpose 
R021102 cells were cultured on collagen coated chamber slides with or 
without dexamethasone until they reached confluence.  Differentiation was 
initiated by changing the culture medium to 2% FBS/F-12.  Four days later 
cells were fixed in situ and processed for immunostaining with desmin and 
fMHC antibodies.  Also representative proliferating cultures before serum 
reduction were fixed for immunostaining.  The in situ staining gives additional 
opportunity to investigate morphological changes during differentiation in 
combination with immuno-staining.   
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Besides desmin, fast myosin heavy chain (fMHC), which is a well 
regarded skeletal muscle differentiation marker, was also used to detect the 
myogenic cells.  fMHC is a sarcomeric protein, whose expression in vitro is 
abundant compared to other myosin isoforms.  Detection of fMHC is sign of 
sarcomeric maturation.  In agreement with FACS data, desmin was 
expressed at higher levels in cells cultured with dexamethasone (Figure 5a 
and c).  This difference was still detectable in cultures in low serum, although 
the desmin positive staining was instead associated with the multinucleated 
myotubes (Figure 5aa and cc) that were barely detectable in proliferating 
cultures.  A similar difference was observed here with fMHC antibody.  
Although some cells could express this protein in proliferating cultures (Figure 
5b and d), the number of cells expressing it significantly increased during 
serum deprivation (Figure 5bb, dd), and the positive staining was associated 
with the same multinucleated structures as with desmin.  Moreover, fMHC 
staining confirmed the same quantitative difference between dexamethasone-
treated and non-treated cultures that was registered by desmin.  The desmin 
and fMHC data together provided the final evidence that dexamethasone 
could increase myocyte proliferation and therefore was beneficial for the 
myoblast pool. 
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a 
aa 
c 
d b 
dd bb 
cc 
Figure 5.  Immunostaining of proliferating and differentiating rat skeletal 
myoblast cultures grown without or with 10-6M dexamethasone (10x 
magnification).  Rat skeletal myoblast cultures were grown without (a, b, aa, bb) 
or with (c, d, cc, dd) dexamethasone throughout the second and third passages. 
Photographs (a-d) represent proliferating cultures, and (aa-dd) show cultures 
after 2 days in differentiation ( serum reduced to 2% FBS).  Samples (a), (b), (aa) 
and (bb) were stained with desmin antibody and (c), (d), (cc) and (dd) with fMHC 
antibody.  
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 Preparation of cell banks 
Cells harvested, pooled together and aliquotted for cryo-preservation 
represent a cell bank.  The generation of cell banks helps to equalize the cells 
injected into different recipients and therefore they reduce differences 
introduced during the study by the variability of donor cells.  We took 
advantage of the availability of syngeneic rats that are immunologically the 
same.  We used such animals to harvest muscles and then pooled the 
muscles together for cell isolation and cultivation.  The isolated cells that were 
of the same tissue origin were then exposed to the same culture conditions in 
passage 1.  During cultivation the cultures were distinguished by an 
identification number that referred to the isolation conditions (Table 3A). 
 
TABLE 3A 
Bank ID R021102M R021102N R121100AT 
Animal weight, g 205-220 210-220 
Muscle number 14 10 
Tissue weight, mg 5900 2050 
Average tibialis anterior weight, mg 421 205 
Yield, 1st passage, x106 17.15 22.9 
Cell yield per gram of tissue, x106 2.90 11.17 
 
TABLE 3B 
Bank ID R021102M R021102N R121100AT 
Dexamethasone, 2nd passage No Yes No 
Yield, 2nd passage, x106 65.67 107.35 117 
Desmin positive, %, 2nd passage 30 66 69 
Vials cryopreserved, 2nd passage 28 26 30 
Cells per vial, 106 1.5 3.5 3 
Table 3.  Cell banks in the study.  3 banks were obtained from two different tissue 
isolates. First passage cells (Table 3A), second passage (Table 3B): R021102 cells 
were grown under two different conditions: in 20% FBS/F-12 with 5 ng/ml of bFGF and 
with 10-6 M dexamethasone or without it.   
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 Usually we prepared cell banks after passage 2 or 3, because passage 
1 does not provide a sufficient number of cells.  Cells older than passage 3 
are not suitable either, because their myoblast content is usually very low due 
to spontaneous differentiation.  During this study we generated 3 different cell 
banks and two of these originated from the same passage 1 cells (Table 3B). 
Passage 1 cultures 
Tissue processing and cultivation of passage 1 cells were identical for 
all cultures.  It included the preplating technique of freshly isolated cells and 
their culturing on collagen coated dishes in 5 ng/ml bFGF/20% FBS.  
Passage 1 cells had already been generated and cryo-preserved for later 
work, when the promoting effect of dexamethasone on the myoblast pool was 
observed.  Although the initial processing and cultivation was the same, the 
cell yield of R021102 passage 1 cells was 3000 cell/mg of tissue compared to 
11000 cells/mg of tissue for R121100AT.  There was a similar difference in 
muscle weight between the two banks.  While in R021102 the average TA 
size was 421 mg, in R122200AT it was only 205 mg.  This difference may be 
related to the age of the animals.  The bigger muscles were derived from the 
older and the smaller muscle from the younger animals, suggesting that the 
cells obtained from the young tissue proliferated faster. 
Passage 2 cultures 
We cultured passage 2 cells either in the presence or in the absence 
of dexamethasone (R021102N and R021102M, respectively).  Consistent 
with the growth promoting effect of the dexamethasone treatment that we 
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observed, both the cell yield (107x106 vs. 66x106) and the desmin content 
(66% and 30%) were higher in cultures treated with dexamethasone than in 
those left untreated.  The third bank designated as R12100AT was generated 
from different passage 1 cells in the absence of dexamethasone and its 
desmin content was 69%.  All these cells were aliquotted (1.5–3.5x106 
cells/cryo-vial), preserved in liquid N2 and transported to Canada on dry ice in 
24 h for implantation. 
 
In vivo study 
 
The use of syngeneic Lewis rats provides great flexibility for the cell 
implantation work.  It allows the isolation of cells from different donor animals 
and their injection into recipient animals as autologous implants, without the 
need to include immuno-suppression therapy. 
 
Study design 
Animal number 
To compare survival and differentiation of skeletal myoblasts in the 
intact myocardium and in the myocardial scar tissue, two animal groups 
received the same treatment and underwent cryoinjury or did not receive 
surgical intervention.  To better follow the fate of the injected cells, in 
additional subgroups the hearts were harvested at 12, 28 and 56 days 
following cell implantation.  The study included 36 animals, with equal number 
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in the infarcted (18) and non-infarcted (18) rats.  Each group consisted of 3 
subgroups that were analyzed at different time-points upon implantation.  In 
addition, each subgroup consisted of 6 animals, because of the potentially 
high mortality of the invasive surgical procedures.  This set up also provided 
us with a statistically significant number of animals for each group. 
Experimental time-line 
The animal study started at the time of cryoinjuring the infarct group 
(Figure 6).   
 
 
The cryo-infarct model was selected, since it had been already 
established in the collaborator laboratory (CRI, Canada).  Additionally the size 
of the infarct is well standardized with this technique and the infarct zone is 
more homogeneous when compared with the ligation model.  Previous 
studies in the same laboratory indicated a prolonged, 2-3 weeks healing 
process after cryoinjury.  Since the survival of injected muscle cells within this 
period had not been yet investigated, we injected the animals 3 weeks after 
Cryoinjured group
   (n=18)  n=6 n=6n=6
Non-cryoinjured group
 (n=18) n=6 n=6n=6
Cryoinjury
   Day -21
Transplantation
     Day 0
Heart Harvest
Day 12  Day 28             Day 56
Figure 6.  Experimental time line of the in vivo part of this study.  Three 
weeks prior to cell implantation 18 animals were cryoinjured and 18 were not 
manipulated at all.  6 animals from each treatment group were sacrificed at 12, 
28 and 56 days after the transplantation.   
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myocardial injury, when the scar is already stable and free of inflammation.  
In a previous study at Genzyme it had been demonstrated that skeletal 
muscle cells become differentiated 2 weeks after implantation and they are 
still detectable at 8 weeks.  However, graft survival had not been 
systematically analyzed either in infarcted or in non-infarcted animals.  
Therefore our follow up time (12, 28 or 56 days) was determined by utilizing 
these observations.  In order to stay in a reasonable time frame, later time 
points were not selected in this study. 
 
Execution of in vivo study 
Infarction 
 Infarcted animals were randomly selected and delivered to the animal 
facility of CRI.  Due to the time consuming infarct procedure, only 4 animals 
were scheduled daily for cryoinjury.  Moreover, all animals in the infarct group 
were processed within 2 weeks.  The non-infarcted group did not get any 
surgery or anesthesia at this time.  Despite the harsh myocardial damage, the 
infarct mortality was zero in the study.   
 
Cell implantation 
In previous studies the optimized injected cell number was 4 million 
per animal.  The total injection dose for the 36 animals therefore would be 
144 million cells.  Since none of the individual banks (R02102M, R02102N, 
R12100AT) could provide such a high number of cells, we decided to 
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combine cells from these banks right before the implantation, which finally 
resulted in the combination of cells shown in Figure 7.   
 
 
Since cells were always simultaneously prepared only for one pair of 
animals (infarcted and non-infarcted, 3 times daily, for a total of 6 animals), 8 
million cells were combined with one cryo-vial from each bank and divided 
into two equal portions only at the end of cell recovery (see MATERIALS AND 
METHODS).   
Although we worked with the combination of cells, in this way we 
eliminated the individual variation of the different cryo-tubes and therefore we 
injected the same cells both into the infarcted and non-infarcted hearts.  The 
average desmin content was about 60% and the average cell number per 
animal was 4.07x106 with 95% viability.  The detailed cell count and viability 
data for each preparation is summarized in Table 4. 
 
R121100AT
3.0x106  vial
69%
R021102N
3.5x106  vial
66%
R021102M
1.5x106 vial
30%
Pooled cells
8.0x106
Cryoinjured
animal
4.0x106
Non-cryoinjured
animal
4.0x106
 
Figure 7.  Cell preparation for 
implantation.  Three vials 
containing 3.5x106 R021102N, 
3.0x106 R021100AT and 1.5x106 
R021102M cells respectively 
were combined together, washed 
and split into 2 equal aliquots of 
4x106 cells and injected a 
cryoinjured and a non-cryoinjured 
animal.   
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Implantation 
day 
 
Daily prep 
 
Total cell number for 
two animals, x106 
 
Viability, 
% 
1 7.8 96 
2 8.48 97 
 
1 
3 7.94 97 
1 8.04 98 
2 8.18 98 
 
2 
3 8 97 
1 8.6 96 
2 8.66 94 
 
3 
3 8.5 95 
1 8.98 94 
2 8.82 95 
 
4 
3 8.74 95 
1 8.84 95 
2 8.36 92 
 
5 
3 8.8 95 
1 9.1 95 
2 8.92 94 
 
6 
3 8.9 95 
Average 8.54 95 
Average per animal 4.27 95 
Highest per animal 4.49 98 
Lowest per animal 3.9 92 
 
At the time of cell implantation the same number of infarcted and non-
infarcted rats were processed daily, usually 6 in total.  All animals received 
cell transplantations in 1 week.  Cell implantation was scheduled 3 weeks +/- 
1 day post-cryoinjury for the infarct group.  In both groups the implantation 
mortality was zero.    
 
Table 4.  Cell number and viability of implants.   
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Tissue collection and microdissection 
 Hearts were harvested at the indicated post-implantation time and 
processed for histology sectioning as described in Heart sectioning section.  
All animals survived the study; therefore, each time point represents 6 
animals/group. 
 
Survival and differentiation of implanted myoblasts in the myocardium 
 
To investigate the fate of injected cells in the scar and the non-
cryoinjured myocardium, tissue sections were analyzed by histochemistry and 
immunohistochemistry. 
 
Heart sectioning 
Due to the large size of the heart we used a dissecting strategy that 
provided us with representative samples from different depth of the whole 
organ.  The immunohistochemical analysis of these sections gave us 
comprehensive information about the fate of implanted cells in normal as well 
as the injured myocardium.  The main steps of the histological sectioning are 
described in Figure 8.  Hearts, trimmed of big vessels and atria were 
sectioned, first by cutting ventricles into 3 equal portions in parallel to the 
short axis of the heart.  These ~3 mm segments were then placed with basal 
surface up into the same histology cassette.  This orientation of samples 
resulted in simultaneous cutting and reviewing of all the three segments in the 
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same slide (Figure 8), reducing section numbers and immunostaining work.  
In the second step the microdissected samples were collected from different 
depth of all segments by skipping 0.5 mm thick tissue between serial cuts.   
Three serial cuts were performed for each non-cryoinjured and 4 from 
each cryoinjured heart.  Each serial cut represents a set of 5 tissue sections 
that are 4 µm thick, with the exception of the first cut, where 10 sections were 
made.   
 
 
Atrium
Segment I
Segment II
Seg III
I
II
III
I II III
I II III
Discard
Discard
Discard
1st Serial
2nd Serial
3rd Serial
4th Serial
Sl
id
e
Slice
Embed
Figure 8.  Micro- and macro-dissections of the heart. Atrium was removed 
from PFA fixed heart and it was further dissected into 3 segments.  The segments 
were placed into a histology cassette and embedded into paraffin.  Then the 
segments were further dissected into 4 serials of 4 µ thick sections discarding 0.5 
mm of tissue between the serials.  The obtained thin sections were then placed on 
histology slides. 
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These extra sections of the first cut were used for Trichrome and H&E 
staining for a general review of the tissue structure and infarct healing.  
Assuming that the unprocessed rat heart long axis is ~1 cm in size, after 
trimming the above described method will survey at least 60-70 % of the 
heart or more due to tissue shrinkage during histological processing. 
 
Histochemistry   
We used Trichrome and H&E stained sections from the first serial cut 
to demonstrate the existence of the infarct and obtain a general analysis of 
the healing process.  Overall, the infarcted area was identified in all animals 
of the infarct group.  Interestingly, a small infarct was also found in one 
animal of the non-infarcted, third time point group.  This animal was excluded 
from further analysis.  Because of the surgical procedure the preferential 
location of the infarcts was in segment II and III, and no infarct was found in 
the basal region in segment I.  The scar area was highly fibrotic with low 
cellularity and did not show any sign of inflammation or tumorous cell 
proliferation.  The subendocardial region of the infarct, however, frequently 
showed calcification, a sign of degenerative tissue process that is often 
associated with infarct healing.  The extent of the myocardial scar in the 
cross-sectioning area was determined by the MetaMorph 5.0r image analysis 
software (Table 5, small insert).  The absolute (pixels) and relative (%) areas 
of infarcts for the individual animals are listed in Table 5 at different time 
points of the study.  Both values showed incremental increases during the 
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study (avg. pixels: 75914day 12 and 131230day 56 or avg. %:16.8day12 and 25.5day 
56), suggesting ongoing ventricular remodeling.   
 
12 days 28 days 56 days 
Infarct size Infarct size Infarct size 
 
 
Animal pixels % pixels % pixels % 
1 50746 12 86895 15 96263 17 
2 64545 14 79271 16 129314 19 
3 88562 16 76058 17 90607 20 
4 80805 17 79880 17 158626 25 
5 85806 19 93378 18 112783 26 
6 85022 23 148443 23 199789 46 
Average 
n=6 
75914± 
15016 
16.8±4 93988± 
27398 
17.6±3 131230± 
41636 
25.4±11
 
Additionally, there was an increasing variation of the infarct size 
between samples 12, 28 and 56 day.  The minimal and maximal infarct size 
varied between 50746 and 85022 in the 12 day group, then progressively 
increased from 76058 to 148443 in the 28 day and 96263 and 199789 in the 
56 day groups.  The larger variation might be related to the individual 
compensatory capacity of the heart, which became more obvious at later 
post-MI time-points.  It may also determine the post-MI survival time.  
Table 5.  Changes in infarct size at different time points of the study.  The infarct 
size was measured in pixels on Trichrome stained sections using MetaMorph 5.0r 
software in each animal (6 animals /time point).  The infarct size was expressed as a 
percentage of the total tissue area.  A small insert shows a representative Trichrome 
stained tissue section, used for absolute (pixels) and relative (%) infarct size 
measurements. 
 
 39
Although we compared different groups of animals, the technical and 
personal standardization of the infarct method allows us to draw the above 
conclusion.   
 
Detection of implanted cells by immunohistochemistry 
Fast myosin heavy chain (fMHC) 
 Due to the lack of markers specific for implanted skeletal muscle cells, 
we detected the implants by determining the ability of the myoblast pool to 
differentiate.  fMHC is one of the markers of the differentiating myoblasts.  It 
is expressed during myotube maturation, and unlike the more universal 
desmin, it appears to be specific for skeletal muscle without being expressed 
in cardiac muscle.  To detect skeletal muscles, we used the MY-32 antibody 
that is frequently applied by other investigators as well (Havenith et al., 1990; 
Rojiani et al, 1998; Kojima et al, 2002).  To compare cell survival and 
differentiation, 7 sections from 3 different tissue depths (non-cryoinjured 
group) and 9 sections from 4 different tissue depths (infarct group) were 
stained and analyzed for fMHC expression in each animal at all experimental 
time points.  Altogether, we processed 7x6 slides from the non-cryoinjured 
and 9x6 slides from the infarcted hearts for each time point.  A typical staining 
pattern of infarcted and non-infarcted samples is shown in Figure 9.   
 
 40
 
 
The low magnification allows an overview of the distribution and 
relation of injected cells to the host tissue.   
a
e f
dc
b
Figure 9. fMHC/DAB staining of non-cryoinjured (a-c) and cryoinjured (d-f) 
hearts, at 12 days (a and d), 28 days (b and e), and 56 days (c and f) after the 
cell implantation (4x magnification). Sections were counterstained with 
hematoxylin. 
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The injected cells usually stayed together, forming smaller or bigger 
groups, mostly one, or with a maximum of 3 groups in one segment.  The 
difference between infarcted and non-infarcted samples was obvious by light 
microscopy, because more fMHC positive cells and more brown staining was 
more abundant in the non-cryoinjured than the cryoinjured group.  This 
difference became more obvious at later time points (Figure 9). 
At a higher magnification the fMHC positive staining was frequently 
visualized as being associated with cells showing long, fiber-like morphology, 
with typical striation pattern and multinucleation (Figure 10).  
 
 
Although there was a difference between individual samples, in general 
more positive cells with more developed morphology were found in the non-
cryoinjured heart samples than in the scar tissue.  The distribution of samples 
with fMHC positive staining in the segments and between the two groups is 
summarized in Table 6.  42 slides from the non-infarcted group (6 animals 
Figure 10.  fMHC/DAB staining of 
non-cryoinjured at 12 days after the 
cell implantation (40x magnification). 
The section was counterstained with 
hematoxylin.   
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with 7 sections/each, one time point group) or 54 slides form cryoinjured 
group (6 animals with 9 sections/each, at each time point) represented 100%.   
 
fMHC positive grafts found in sections, % 
Non-Cryoinjured animals Cryoinjured animals 
 
 
Time point Segment II  Segment III Segment II Segment III 
12 days 29%  
n=42 
79% 
n=42 
20%  
n=54 
76% 
n=54 
28 days 26% 
n=42 
71% 
n=42 
0%  
n=54 
67% 
n=54 
56 days 21% 
n=35 
81% 
n=35 
4%  
n=54 
37% 
n=54 
 
The fMHC positive cells were identified in the middle (II) and in the apical 
(III) segments, corresponding to the injection sites and they were never found 
in the top segment (I) at the basal area of the heart.  In contrast, the majority 
of the positive staining was identified in Segment III in all cases.  In this 
segment ~2/3 of the samples contained positive area in the non-infarcted 
group, with small variation between time points (71-81%).  In the cryoinjured 
group the number of samples with fMHC positive cells decreased from 76% 
to 37% as a function of time.  Similar distribution was observed in Segment II.  
While ~1/3 of the samples contained positive areas in the non-infarcted group 
and remained the same during the study, the infarcted hearts had similar 
Table 6.  Distribution of fMHC positive slides in non-cryoinjured vs. cryoinjured 
myocardium at different time points of the study.  The reviewed number of sections is 
indicated by n.  The number of fMHC positive sections is expressed as a % of n value. 
Segment II and segment III were evaluated separately.  No fMHC positive grafts were found 
in segment I.   
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numbers of positive samples (20%) compared to control only at an early time 
point.  Although at 12 day there was not any significant difference between 
the two groups, later at 28 or 56 days fewer samples contained positive cells 
in the infarcted group as opposed to the non-cryoinjured.   
To further quantify this difference, slides containing positive staining by 
light microscopic analysis were processed for image quantification by the 
MetaMorph program.  The average pixel number for each treatment group is 
summarized in Figure 11.   
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Figure 11.  Distribution of fMHC positive area of non-cryoinjured (red bar) 
and cryoinjured (blue bar) groups at different time points.  The average 
fMHC positive area was expressed in pixels, error bars show ±SE.  
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This was higher at each time point for the non-injured (7800, 4300, 6200 
pixels), than for the injured group (~2000 pixels), resulting 5-6x difference 
between the two groups.  The difference was significant (p<0.05) for each 
time point, using a paired t-test.  The relation of fMHC positive area to the 
whole cross section area is summarized in Table 7.  These data indicate that 
4 million injected cells can fill up ~1-1.3% of the tissue area in non-cryoinjured 
myocardium, and only 0.27 % or less in the infarcted heart.  The relation of 
the fMHC positive area to the infarct size was also estimated by expressing 
the fMHC pixel area as a % of the scar pixel area.  The scar size was 
determined on Trichrome stained sections.  This value varied between 0.2%-
6% for the individual animals.  Some reduction of the fMHC positive area was 
also found in non-infarcted hearts at the 3 time points, however, this decline 
in fMHC content was not significant by the paired t-test. 
 
Average relative fMHC positive area per animal 
group, % 
 
Time Point Non-cryoinjured animals Cryoinjured animals 
 
P value 
12 days 1.36±0.36 0.27±0.09 P<0.001 
28 days  1.05±0.29 0.12±0.03 P<0.001 
56 days 1.07±0.37 0.07±0.03 P<0.001 
 
 
Table 7.  Relative fMHC positive area in cryoinjured and non-cryoinjured myocardium 
at 12, 28 and 56 day time points.  An average positive area in a cross-section was 
determined for each individual animal, and then an average for each group was calculated.
Statistical analysis was performed by paired t-test (P value).  The measurements were made 
using MetaMorph 5.0r software.   
 
 45
Slow MHC (sMHC) 
To investigate whether injected cells could express other myosin 
isoforms besides fMHC, we used immunostaining for slow myosin heavy 
chain.  Detection of sMHC is more difficult than that of fMHC, because sMHC 
is the main myosin isoform of the host tissue.  Therefore all sMHC staining 
was evaluated in parallel with fMHC staining (Figure 12,  a and b).   
 
 
 
It was found that both the infarcted and non-infarcted hearts expressed 
the sMHC as well as the fMHC isoforms with a similar expression pattern 
(data not shown).  In spite of this, due to the high tissue background, sMHC 
detection could not be used for implant survival study.  Moreover, the 
expression of sMHC in the implant is restricted to the fMHC positive area, 
indicating that there were no more differentiated cells in the infarcted heart 
than those detected by fMHC. 
a b
Figure 12.  sMHC/DAB (a) and fMHC (b) staining of two consecutive sections in 
cryoinjured heart at 28 days after cell implantation (4x magnification).  The sections 
were counterstained with hematoxylin. 
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Myogenin 
 Although myogenin is a transiently appearing transcriptional factor of 
early muscle differentiation, its expression was observed in cells implanted in 
both infarcted and non-infarcted hearts at all time points of the study (data not 
shown).  However, as expected, myogenin staining was most abundant at the 
earliest investigated time point (12 days) and less plentiful at later time points.  
Myogenin staining always labeled the same graft area as the fMHC staining 
(Figure 13, a and b). 
 
 
The positive nuclear staining occasionally labeled multinucleated 
structures (Figure 14).  The myogenin staining gave additional evidence of 
the presence of implanted cells, although detection of the implant by fMHC 
was easier than by myogenin (compare the limited nuclear with the abundant 
cytoplasmic staining). 
a b
Figure 13.  Myogenin/DAB (a) and fMHC (b) staining of two consecutive sections of 
the non-cryoinjured myocardium at 12 days after the cell implantation (4x 
magnification).  The sections were counterstained with hematoxylin.  
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Implanted cells cannot trans-differentiate into cardiac phenotype 
To investigate the relation of implanted cells to the host myocardium, 
the characteristic cardiac marker cardiac troponin I staining was used.  
Troponin I is a calcium binding protein, which therefore regulates muscle 
contraction.  The cardiac specific isoform of this protein is not expressed in 
skeletal muscle.  The antibody gave a homogenous tissue staining of heart 
muscle as shown in Figure 15, however, there was a negatively stained area, 
which by fMHC staining can be identified as the injection site (Figure 15, a 
and b).  It thus appears that the injected cells did not express cardiac 
Troponin I, indicating that no trans-differentiation of the injected cells from 
skeletal to cardiac phenotype occurred.   
 
Figure 14.  Myogenin/DAB 
staining of the non-
cryoinjured myocardium at 
12 days after cell 
implantation (40x 
magnification).  The section 
was counterstained with 
hematoxylin. 
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Although cardiac Troponin I was investigated only in a subset of the 
samples, all samples within this subset recorded the same result, 
independently whether the infarcted or non-infarcted samples were stained 
and at which time point of the study. 
 
Figure 15.  Cardiac Troponin I/DAB (a) and fMHC (b) staining of two consecutive 
sections of the non-cryoinjured myocardium at 56 days after the cell implantation 
(4x magnification).  The sections were counterstained with hematoxylin.  
a b
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DISCUSSION 
 
We used a syngeneic rat cryoinjury model to measure the survival and 
differentiation of cultured myoblasts in the cryoinjured and non-cryoinjured 
myocardium.  First we isolated skeletal myoblasts from TA muscles and 
propagated them under tissue culture conditions using bFGF in combination 
with dexamethasone as growth factors.  We found that 10-6 M 
dexamethasone with 5 ng/ml bFGF can triple the yield of muscle cells when 
compared to cultures with the same concentration of bFGF without 
dexamethasone.  This is because dexamethasone induced the proliferation of 
the desmin positive pool (myoblast), as was determined by desmin FACS 
analysis.  Although the growth inducing mechanism of dexamethasone is 
poorly understood, similar observations have already been reported by others 
(Guerriero et al., 1978; Guerriero et al., 1980; Gossett et al., 1988) and also 
in our laboratory in human cells (unpublished observation).  TGF-beta, 
another growth factor, also affected the myoblast content, but the lack of 
growth promotion was disadvantageous to obtaining large numbers of 
myoblasts in culture.   
 
To determine the myoblast content of the individual cultures, desmin 
as a primary marker was applied (Allen et al., 1991).  The advantage of using 
desmin expression is that the myogenic cells constituitively express it, as 
opposed to myogenin, which appears only transiently in myoblasts committed 
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to differentiate.  The suitability of desmin as a marker was further supported 
by differentiation test results, which showed more myotube formation and 
more fMHC or myogenin positive cells in the higher desmin containing 
cultures.  
 
The disadvantage of desmin is its ubiquitous expression in every 
muscle type, including cardiac muscle, which does not allow the specific 
detection of injected cells by this marker in the myocardium.  Since we did not 
want to manipulate these cells by pre-labeling them with BrdU, GFP etc., our 
detection system was based on the in vivo differentiation potential of 
myoblasts.   
Fast MHC is a myosin isoform, whose expression is more abundant 
both in vitro and in denervated muscle, when compared to other myosin 
isoforms.  Additionally this myosin isoform is not present in cardiac myocytes, 
allowing easy detection of implanted cells in the host tissue.  We also 
developed a tissue dissecting strategy to search for the implanted cells in the 
whole heart by reviewing a limited number (7-9) of sections from each heart.  
Moreover, we adapted an image analysis software, MetaMorph 5.0r, to 
quantify the graft size.  Applying fMHC immunostaining on the representative 
section set, the grafted cells showed the same topographical localization in 
each animal, mostly in Segments III and II, corresponding to their injection 
site.  This suggests low individual variation of the injection and reliability of 
the detection.  Differentiated myoblasts appeared at 12 day in both groups, 
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and remained detectable during the whole study.  This indicates that in spite 
of the poor tissue environment the maturation process of the myoblasts did 
not change.  In contrast, there was a significant difference in the size of the 
newly formed tissue when comparing injured and non-injured hearts.  Skeletal 
myocytes in the injured muscle formed a looser, smaller size group(s), 
resulting in at least 5-6x smaller implant size both in absolute (pixels) and 
relative numbers (% of total tissue section area) compared to control.  This 
difference might have occurred for several reasons.  One reason may be the 
hostile environment in the damaged tissue, which does not provide sufficient 
nutrients for the matured muscle cells as compared to the normal tissue.  
Another explanation may be related to tissue stiffness.  The fibrotic area in 
the cryoinjured heart is leakier than the normal muscle, therefore this tissue at 
the time of injection does not hold the implanted cells, resulting in significant 
loss at the time of delivery.  It is also possible that the proximity of 
cardiomyocytes gives more protection for the implanted cells in normal 
muscle.  It may be also because of the more direct mechanical and electrical 
activation of the non-cryoinjured myocardium, which may be particularly 
important for skeletal muscle cells that are maintained by electro-chemical 
stimuli through the neuromuscular junction.  Although there was not any 
significant difference in graft size at various time points within the non-injured 
group, there was a non-significant decrease in size between 12 day and 28 
day groups, which was stabilized by 56 day time point.  This observation may 
also be related to the above, because the injected cells do not show coupling 
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with the host tissue, as shown by the lack of gap junction protein connexin 43 
expression (Reinecke et al., 2000, and also in our laboratory).  Although 
these cells do not form cardiac gap junctions and do not trans-differentiate 
into cardiac myocytes as shown by the negative cardiac troponin I staining, 
by an unknown mechanism they support cardiac function (Jain et al., 2001; 
Taylor et al., 1998; Atkins et al., 1999; Scorsin et al., 2000).  One of the 
proposed mechanisms may occur is that by increasing wall thickness of the 
damaged muscle, therefore they prolong or slow down the passive dilatation 
of the left ventricle.  It is also possible that they became electro-mechanically 
activated by the myocardium, and induced for secondary contraction, which 
ultimately contributes to a better cardiac work.   
The use of fMHC immunostaining to detect graft survival and 
differentiation has limitations, because it does not give information about the 
population of injected cells that are desmin negative, undifferentiated cells or 
myocytes expressing MHC isoforms other than fMHC.  The desmin negative 
population in equivalent human skeletal muscle cell strains was not identified 
with endothelial, smooth muscle or fat cell markers, but stained positively for 
the stromal cell marker TE-7, therefore cognate rat cells most likely are 
fibroblasts (T. Masi-Joseph, Genzyme Corp., unpublished observation).  Our 
detection system does not identify them and they are not able to actively 
contract.  In spite of this, the cardiac function supporting effect of fibroblasts 
has been reported (Hutcheson et al., 2000).  Whether these cells show the 
same survival in the injured as in the non-cryoinjured myocardium or they are 
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less sensitive to factors than the myoblasts it is not known and requires a 
different labeling system to follow their fate after implantation.  We believe 
that most of differentiated skeletal myoblasts primarily expressed fMHC.  
Staining with sMHC antibody indicated that these cells in some cases also 
co-expressed the latter myosin isoform, however there were not a significant 
number of only sMHC-expressing cells.  Other myosin isoforms, typical for 
embryogenesis and postnatal development cannot be detected by 
immunostaining due to the lack of the specific antibodies.   
 In summary, our data indicate that skeletal myoblasts have a 
substantial potential to survive and differentiate in the normal and injured 
heart, but the quality of the host tissue limits this potential.  The system 
described here appears to be a useful model to test new approaches (genetic 
modification of implanted cells, dose curve study, selection of post-
implantation time points, changing injection technique etc.) to improve the 
survival and differentiation of these cells, therefore to further increase their 
therapeutic effect. 
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